Sanofi SA vs Tripadvisor Inc Common Stock — how do they compare? Sanofi SA trades at $44.05 (market cap $104.83B), while Tripadvisor Inc Common Stock trades at $13.82 (market cap $1.68B). The key difference: Sanofi SA is far larger — about 62.4× Tripadvisor Inc Common Stock's market cap, and Sanofi SA pays a 5.5% dividend while Tripadvisor Inc Common Stock pays none. Which is the better fit depends on your goals.
| SNY | TRIP | |
|---|---|---|
Market Cap | $104.83B | $1.68B |
Sector | Health | Consumer Cyclical |
52-Week High | $52.34 | $19.14 |
52-Week Low | $41.33 | $9.24 |
Enterprise Value | $121.32B | $1.80B |
Dividend Yield | 5.5% | — |
Trailing returns across standard periods
Latest headlines on both assets
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →TripAdvisor is the world's leading travel metasearch company. The website offers 1 billion reviews and information on about 8 million accommodations, restaurants, experiences, airlines, and cruises. In 2021, 74% of revenue came from the company's core segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 20% of sales in 2021, and TheFork, its dining brand, represented 9% of revenue (about 3% of sales were intersegment, which are eliminated from consolidated revenue).
Read more on TRIP →